JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: In hematological malignancy, Icaritin strongly inhibits growth of primary chronic myeloid leukemia (CML) cells in vitro and in vivo by regulating the MAPK/ERK/JNK and JAK2/STAT3/AKT pathways [20].